Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-a, b, c) phenotype

James A. Rybski, Catherine S Perry, Thomas P Miller, Scott M. Lippman, Dan L. Mcgee, Thomas M. Grogan

Research output: Contribution to journalArticle

7 Citations (Scopus)

Abstract

Ninety-nine consecutive diffuse large cell lymphoma (DLCL) patients were studied by immunohistochemistry to determine whether clinical outcome was predicted by major histocompatibility complex (MHC) antigen phenotypic expression. Statistically significantly shorter disease free survival (p = 0.005), but not overall survival (p = 0.47), was observed when patient lymphomas failed to express class I MHC antigens. We also observed significantly reduced survival of class II MHC HLA-DP negative patients (p = 0.038). This extends our previous finding of poor outcome with absent class II MHC HLA-DR in DLCL1 to other MHC antigens and demonstrates that the phenomenon of defective class II antigen expression comprises 16% of these DLCL patients. Known clinical parameters predictive of prognosis were equally distributed between phenotypic groups. These findings indicate that aberrancy of immune phenotype in DLCL is critical to patient outcome and we speculate that loss of MHC expression may confound host immunosurveillance and tumor containment.

Original languageEnglish (US)
Pages (from-to)31-38
Number of pages8
JournalLeukemia and Lymphoma
Volume6
Issue number1
DOIs
StatePublished - 1991

Fingerprint

HLA-DP Antigens
Lymphoma, Large B-Cell, Diffuse
HLA-DR Antigens
Major Histocompatibility Complex
Phenotype
Histocompatibility Antigens
Immunologic Monitoring
Histocompatibility Antigens Class I
Survival
Histocompatibility Antigens Class II
Disease-Free Survival
Lymphoma
Immunohistochemistry

Keywords

  • Immunochemistry
  • Lymphoma
  • Major histocompatibility complex
  • Prognosis
  • Therapy

ASJC Scopus subject areas

  • Hematology
  • Oncology
  • Cancer Research

Cite this

Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-a, b, c) phenotype. / Rybski, James A.; Perry, Catherine S; Miller, Thomas P; Lippman, Scott M.; Mcgee, Dan L.; Grogan, Thomas M.

In: Leukemia and Lymphoma, Vol. 6, No. 1, 1991, p. 31-38.

Research output: Contribution to journalArticle

@article{62933a40d6ab407dad24eadef720c09a,
title = "Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-a, b, c) phenotype",
abstract = "Ninety-nine consecutive diffuse large cell lymphoma (DLCL) patients were studied by immunohistochemistry to determine whether clinical outcome was predicted by major histocompatibility complex (MHC) antigen phenotypic expression. Statistically significantly shorter disease free survival (p = 0.005), but not overall survival (p = 0.47), was observed when patient lymphomas failed to express class I MHC antigens. We also observed significantly reduced survival of class II MHC HLA-DP negative patients (p = 0.038). This extends our previous finding of poor outcome with absent class II MHC HLA-DR in DLCL1 to other MHC antigens and demonstrates that the phenomenon of defective class II antigen expression comprises 16{\%} of these DLCL patients. Known clinical parameters predictive of prognosis were equally distributed between phenotypic groups. These findings indicate that aberrancy of immune phenotype in DLCL is critical to patient outcome and we speculate that loss of MHC expression may confound host immunosurveillance and tumor containment.",
keywords = "Immunochemistry, Lymphoma, Major histocompatibility complex, Prognosis, Therapy",
author = "Rybski, {James A.} and Perry, {Catherine S} and Miller, {Thomas P} and Lippman, {Scott M.} and Mcgee, {Dan L.} and Grogan, {Thomas M.}",
year = "1991",
doi = "10.3109/10428199109064876",
language = "English (US)",
volume = "6",
pages = "31--38",
journal = "Leukemia and Lymphoma",
issn = "1042-8194",
publisher = "Informa Healthcare",
number = "1",

}

TY - JOUR

T1 - Prediction of outcome in diffuse large cell lymphoma by the major histocompatibility complex class II (HLA-DR, DP, DQ) and class I (HLA-a, b, c) phenotype

AU - Rybski, James A.

AU - Perry, Catherine S

AU - Miller, Thomas P

AU - Lippman, Scott M.

AU - Mcgee, Dan L.

AU - Grogan, Thomas M.

PY - 1991

Y1 - 1991

N2 - Ninety-nine consecutive diffuse large cell lymphoma (DLCL) patients were studied by immunohistochemistry to determine whether clinical outcome was predicted by major histocompatibility complex (MHC) antigen phenotypic expression. Statistically significantly shorter disease free survival (p = 0.005), but not overall survival (p = 0.47), was observed when patient lymphomas failed to express class I MHC antigens. We also observed significantly reduced survival of class II MHC HLA-DP negative patients (p = 0.038). This extends our previous finding of poor outcome with absent class II MHC HLA-DR in DLCL1 to other MHC antigens and demonstrates that the phenomenon of defective class II antigen expression comprises 16% of these DLCL patients. Known clinical parameters predictive of prognosis were equally distributed between phenotypic groups. These findings indicate that aberrancy of immune phenotype in DLCL is critical to patient outcome and we speculate that loss of MHC expression may confound host immunosurveillance and tumor containment.

AB - Ninety-nine consecutive diffuse large cell lymphoma (DLCL) patients were studied by immunohistochemistry to determine whether clinical outcome was predicted by major histocompatibility complex (MHC) antigen phenotypic expression. Statistically significantly shorter disease free survival (p = 0.005), but not overall survival (p = 0.47), was observed when patient lymphomas failed to express class I MHC antigens. We also observed significantly reduced survival of class II MHC HLA-DP negative patients (p = 0.038). This extends our previous finding of poor outcome with absent class II MHC HLA-DR in DLCL1 to other MHC antigens and demonstrates that the phenomenon of defective class II antigen expression comprises 16% of these DLCL patients. Known clinical parameters predictive of prognosis were equally distributed between phenotypic groups. These findings indicate that aberrancy of immune phenotype in DLCL is critical to patient outcome and we speculate that loss of MHC expression may confound host immunosurveillance and tumor containment.

KW - Immunochemistry

KW - Lymphoma

KW - Major histocompatibility complex

KW - Prognosis

KW - Therapy

UR - http://www.scopus.com/inward/record.url?scp=0026356542&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0026356542&partnerID=8YFLogxK

U2 - 10.3109/10428199109064876

DO - 10.3109/10428199109064876

M3 - Article

AN - SCOPUS:0026356542

VL - 6

SP - 31

EP - 38

JO - Leukemia and Lymphoma

JF - Leukemia and Lymphoma

SN - 1042-8194

IS - 1

ER -